Ovarian cancer drugs in China mainly include five categories: PARP inhibitors, anti-angiogenic therapies, antibody-drug conjugates (ADCs), PD-1 immunotherapy, and chemotherapy, covering first-line treatment, maintenance therapy, recurrent disease, and platinum-resistant ovarian cancer. Ovarian cancer is one…
What are the treatment options for Duchenne muscular dystrophy? Current treatment options for Duchenne muscular dystrophy include corticosteroids, exon-skipping therapies, gene therapy, rehabilitation, and supportive care. Treatment is individualized based on the patient’s age, disease…
This guide explains what GLP-1 drugs are available in China, including approved GLP-1 receptor agonists, dual-target therapies, oral medications, and combination products. GLP-1 medications have become one of the hottest topics in the global pharmaceutical…
Cancer treatment is often a long and uncertain journey. Global pharmaceutical distributor DengYueMed has organized the 10 key questions cancer patients ask to help patients better understand cancer treatment pathways and make more informed decisions…
In 2024, several new lung cancer treatments, including Unecritinib Fumarate Capsules, Tarlatamab, Zenocutuzumab, Lazertinib and Amivantamab Combination, and Durvalumab, were approved, offering groundbreaking options for patients with various types of lung cancer. Drug Name Brand…
